SESSION 1 WORKSHOPS SEPTEMBER
07
THURSDAY
WHERE ARE WE WITH AN HIV CURE STRATEGY FOR WOMEN?
Presented by: Danielle M Campbell, AVAC, PxROAR, Los Angeles California, Los Angeles Women’s HIV/ AIDS Task Force + Julia Patterson, AVAC PxROAR, Cleveland, Ohio + David Evans, Project Inform, Los Angeles, California + Pedro Goicochea, Forum for Collaborative HIV Research, Washington, DC + Moisés Agosto, NMAC, Washington DC + Dawn Averitt, Women’s Research Initiative on HIV/ AIDS, Norwich, VT + Catalina Ramirez, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina + Karine Dubé, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina Location: Union Station, Meeting Level 3 Track: Cis & Trans Women Level: Beginner
HIV/AIDS morbidity and mortality are a top health burden of cisgender and transgender women. Black and Latina women are most affected, representing 76% of all diagnoses among cisgender women in 2015, and transgender women have almost 50 times the odds of living with HIV compared to other reproductive age adults. Despite this, women are drastically underrepresented in HIV cure research studies. Not since Timothy Brown in 2007, have we seen any new reported cases of sterilizing cure – complete elimination of the HIV virus in the body.There are multiple HIV cure research methods being investigated, including latency-reversing agents, gene modification, stem cell transplantation, immune-based strategies, and some HIV reservoir assessments without any investigational agents. Current research has pointed to estrogen and sex-based differences affecting the establishment and distribution of the HIV reservoir.The need for a cure is critical, but will HIV cure strategies include women? CDC’S UPDATE ON PREVENTION MESSAGES AND TOOLS
Presented by: Jo Stryker, Cindy Lyles, Sar a Bresse, Vasavi Thomas, David Whittier, Jocelyn Patterson, Kathleen Green, Laur a Chiang, Laur a McElroy, Jeffrey Kemp Rinderle, Jocelyn Taylor, Euna M. August, and David Purcell, Centers for Disease Control and Prevention, Atlanta, GA Location: Capitol, Meeting Level 4 Pathway: Centers for Disease Control and Prevention Level: Intermediate
The expansion of behavioral and biomedical HIV prevention strategies has resulted in more HIV prevention options than ever before. Accordingly, prevention messages have become increasingly complex. As the science evolves, CDC continues to update its messages, materials and tools to ensure that resources meet the needs of distinct audiences. This process includes scientific reviews, translation of science into messages for distinct audiences, message testing, materials development and testing, and message dissemination. In this session, CDC will discuss the latest updates to its scientific review process, focusing on viral suppression, and how the science was translated into messaging. CDC will also present updated and new HIV prevention tools including the recently updated comprehensive HIV Risk Reduction Tool, various new PrEP training resources for healthcare providers and their patients, and a comprehensive HIV care resource kit for providers of gender-affirming health care and their transgender patients.
40
PROVIDING PREP/PEP TO MINORITY POPULATIONS: AN AGENCY-WIDE EFFORT
Presented by: Timothy Au, LMSW, Apicha Community Health Center, New York, NY + Melanie Dulfo, LMSW, Apicha Community Health Center, New York, NY + Phillip Miner, MLS, Apicha Community Health Center, New York, NY Location: Mint, Meeting Level 4 Pathway: Race: Asian & Pacific Islander Level: Intermediate
In this workshop, staff of Apicha Community Health Center describe how they successfully target and provide PrEP/PEP to people of color, especially Asian and Pacific Islanders. Topics include community health education through outreach and digital marketing, HIV/STI testing and linkage to primary care, and providing navigation to address the common barriers associated with obtaining a prescription and treatment adherence. OVERVIEW OF VIRAL HEPATITIS: HEPATITIS B, HEPATITIS C, AND HIV COINFECTIONS
Presented by: Robin Lord Smith, Hepatitis C Association and Help-4-Hep; + Chari Cohen, Hepatitis B Foundation, Doylestown, PA + Andrew Reynolds, Project Inform, San Fr ancisco, CA Location: George Washington, Meeting Level 1 Pathway: Hepatitis Level: Beginner
People living with or who are risk for HIV are also at increased risk for hepatitis B (HBV) and hepatitis C (HCV). This session will provide an overview HBV and HCV, including epidemiology, transmission, prevention, and treatment. The overview of HCV will include an emphasis on the prevention and treatment needs of people who inject drugs.The overview of HBV will include a review of vaccination and prevention of mother-to-child transmission. We will also focus on the risk for and prevention of sexual transmission of HCV in persons living with HIV.This overview is appropriate for people with all levels of knowledge of viral hepatitis. HIV AND HCV CO-INFECTION: DISCUSSING THE CURE FOR HCV
Presented by: Letha Healey, MD, HRSA/HAB, Rockville, MD + Sar a Woody, HRSA/HAB, Rockville, MD + Pamela Belton, HRSA/HAB, Rockville, MD Location: Treasury, Meeting Level 4 Pathway: HHS SMAIF Level: Beginner
People living with HIV (PLWH) are a priority population in the National Viral Hepatitis Action Plan. About 25% of PLWH are co-infected with HCV.This more than triples their risk for liver-related death.The opioid epidemic has led to an increase in injection drug use and HCV infections, putting over 220 U.S. counties at risk for HIV and HCV outbreaks. This session provides an overview of data on HIV and HCV co-infection, who is affected, the impact HCV co-infection has on treatment options, disease progression, and death among people living with HIV. We will